Nagengast et al. [19],[24] showed that high-VEGF-producing SKOV-3 ovarian tumor xenografts had a higher uptake of 89Zr-bevacizumab than of 89Zr-labeled IgG, which served as a control. The gene discussed is VEGFA; the disease is ovarian neoplasm.